Overview
GH market data
Price History
GH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $40.35 – $172.61 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $22.8K · P/B 20.69 · P/S 21.08.
Company news
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035Globenewswire Inc · Jul 22, 2026, 11:00 AM
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190Benzinga · Jul 16, 2026, 12:00 PM
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205Benzinga · Jul 14, 2026, 11:55 AM
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175Benzinga · Jul 9, 2026, 5:05 PM
Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215Benzinga · Jul 8, 2026, 4:10 PM
Evercore ISI Group Maintains Outperform on Guardant Health, Raises Price Target to $200Benzinga · Jul 6, 2026, 4:15 PM
B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $190Benzinga · Jul 6, 2026, 11:00 AM
Bernstein Maintains Outperform on Guardant Health, Raises Price Target to $200Benzinga · Jul 2, 2026, 2:35 PM
BTIG Maintains Buy on Guardant Health, Raises Price Target to $190Benzinga · Jul 1, 2026, 4:55 PM
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160Benzinga · Jun 29, 2026, 2:05 PM